Raymond James Reinstates Outperform on Harmony Biosciences, Announces $40 Price Target
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Danielle Brill has reinstated an Outperform rating on Harmony Biosciences (NASDAQ:HRMY) with a price target of $40.
October 10, 2024 | 1:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Raymond James has reinstated an Outperform rating on Harmony Biosciences with a $40 price target, indicating a positive outlook for the stock.
The reinstatement of an Outperform rating by a reputable analyst and a specific price target of $40 suggests a positive sentiment towards Harmony Biosciences. This could lead to increased investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100